Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study

• DOI: 10.1136/esmoopen-2019-000535
• Publication Date: 2019-10-14T09:44:16Z
• Authors: Natalia Dengina; Timur Mitin; Sergey Gamayunov; Sufia Safina; Yuliya Kreinina; Ilya Tsimafeyeu
• Keywords: Clinical endpoint; Abscopal effect

Tyrosine kinase inhibitors (TKIs) and checkpoint have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are necessary to improve these agents' efficacy.Patients with stable disease at least 4 months on TKI or were included. Stereotactic body radiotherapy (SBRT) was delivered an organ comparable lesions, where one lesion in the target other intentionally left untreated (control lesion). Response both lesions scored using Evaluation Criteria Solid Tumors V.1.1 criteria 2 after completion SBRT. The primary endpoint rate SBRT adverse events, secondary endpoints included reduction size.17 enrolled (14 men 3 women, median age: 54.5 years old). lungs (n=5), bones (n=4), lymph nodes liver (n=1), (RCC) (n=1) locally recurrent RCC (n=2). equivalent dose Gy alpha beta ratio 2.6 114 Gy. With follow-up 8 months, cumulative SBRT-related toxicity (grade 1) 12% (n=2), consisting oesophagitis skin erythema. No grade higher detected. Radiographic response seen 13 (76%), 5 (29%) partial (47%), including abscopal effect 1 patient. Control remained 16 patients. difference between control judged by mean sizes before statistically significant (p<0.01). Fraction size 10 greater associated (p<0.01).Extracranial mRCC treated is well tolerated could be effective.NCT02864615.